MP79 - MP79: Prostate Cancer: Advanced (including Drug Therapy) IV

Poster Presenter(s)

• 

  Mohamed Ahmed, MD

  Research Fellow
  Mayo Clinic

  PDF Poster Slides and Audio
• 

  Carlo Bravi, MD

  San Raffaele Hospital

  PDF Poster Slides and Audio
• 

  Alexander Cole, MD

  Resident
  Brigham and Women's Hospital

  PDF Poster Slides and Audio
• 

  Giorgio Gandaglia

  Department of Urology, San Raffaele Hospital

  PDF Poster Slides and Audio
• 

  Jiun Hung Geng, MD

  Brigham and Women's hospital

  PDF Poster Slides
• JH

  Jason Hu

  Poster
• PJ

  Praveen Kumar Jaiswal
• PJ

  Patricia John
• TK

  Tariq A. Khemees
• NK

  Natalija Kovacevic, MD

  Henry Ford Hospital/Health System

  PDF Poster Slides and Audio
• JK

  Jatinder Kumar
• 

  Ronan Le Moigne

  PDF Poster Slides and Audio
• JL

  Jie Luo
• 

  Morgan Schubbe, MD,BS

  University of Iowa Hospitals and Clinics

  PDF Poster Slides and Audio
• 

  Eswar Shankar, PHD

  Case Western Reserve University

  PDF Poster Slides and Audio
• AS

  Akshay Sood
• 

  Yasemin Ural, MD

  University hospital of Cologne

  Poster
• AW

  Allison Wheeler
• 

  XINYAN YANG, MBBS

  Singapore General Hospital

  PDF Poster Slides and Audio

Presentations:

• 7:00 AM – 9:00 AM

  MP79-01: External validation of the 2019 Briganti nomogram for the identification of prostate cancer patients who should be considered for an extended pelvic lymph node dissection
  Giorgio Gandaglia
• 7:00 AM – 9:00 AM

  MP79-02: Performance characteristics of PET/CT scan in men treated with salvage lymph node dissection for recurrent prostate cancer: a per patient analysis with pathological confirmation according to each area of dissection.
  Carlo Bravi, MD
• 7:00 AM – 9:00 AM

  MP79-03: Drug repurposing approach for developing novel therapy for castration resistant prostate cancer
  Eswar Shankar, PHD – Case Western Reserve Unv
• 7:00 AM – 9:00 AM

  MP79-04: The preclinical characterization and development of EPI-7386, an N-terminal domain androgen receptor inhibitor, for the treatment of prostate cancer
  Ronan Le Moigne
• 7:00 AM – 9:00 AM

  MP79-05: Neoadjuvant Apalutamide (ARN-509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer (NEAR) phase II trial
  XINYAN YANG, MBBS
• 7:00 AM – 9:00 AM

  MP79-06: COMPARATIVE EFFICACY OF ENZALUTAMIDE, APALUTAMIDE AND DAROLUTAMIDE FOR TREATMENT ON NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER: A NETWORK META-ANALYSIS
  Jatinder Kumar
• 7:00 AM – 9:00 AM

  MP79-07: Validation and implementation of a mobile app decision support system for quality assurance of tumor boards. Analyzing the concordance rates for prostate cancer at a multidisciplinary tumor board of a Tertiary Referral Centre.
  Yasemin Ural, MD
• 7:00 AM – 9:00 AM

  MP79-08: Identifying patients that may benefit from addition of bicalutamide to salvage radiation therapy in the setting of biochemical failure after radical prostatectomy
  Natalija Kovacevic, MD
• 7:00 AM – 9:00 AM

  MP79-09: ANTI-ANDROGEN THERAPY OVERCOMES THE TIME-DELAY IN INITIATION OF SALVAGE RADIATION THERAPY AND RESCUES ONCOLOGICAL OUTCOMES IN MEN WITH RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY
  Akshay Sood
• 7:00 AM – 9:00 AM

  MP79-10: A Smartphone-based Mobile Health App to Address the Adverse Effects of Androgen Deprivation Therapy in Men with Prostate Cancer
  Alexander P. Cole, MD – Brigham & Womens Hospital Urology Div
• 7:00 AM – 9:00 AM

  MP79-11: FEASIBILITY OF CONSOLIDATIVE SURGERY IN OLIGOMETASTATIC AND LOCALLY ADVANCED PROSTATE CANCER: INITIAL SURGICAL RESULTS FROM PHASE II TRIAL OF NEOADJUVANT THERAPY AND PSMA PET/MRI IMAGING
  Tariq A. Khemees
• 7:00 AM – 9:00 AM

  MP79-12: Microbiome of Metastatic Prostate Cancer Lymph Nodes
  Allison Wheeler
• 7:00 AM – 9:00 AM

  MP79-13: Eukaryotic translation initiation factor 4 gamma 1 (EIF4G1) is upregulated in ENZ resistant PCa and plays an important role in aggressive phenotype
  Praveen Kumar Jaiswal
• 7:00 AM – 9:00 AM

  MP79-14: LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling
  Jie Luo
• 7:00 AM – 9:00 AM

  MP79-15: Predictors of Health-Related Quality of Life in Patients on Androgen Deprivation Therapy for Metastatic Prostate Cancer
  Morgan E. Schubbe, MD,BS – The Univ of Iowa Hospitals and Clinics
• 7:00 AM – 9:00 AM

  MP79-16: Long-term results of cytoreductive radical prostatectomy in men with hormone-naive, low volume metastatic prostate cancer(mhnPCA)
  Patricia John
• 7:00 AM – 9:00 AM

  MP79-17: Addition of carboplatin to chemotherapy regimens for metastatic castrate resistant prostate cancer in post-2nd generation hormone therapy setting: does it improve survival?
  Mohamed El Sayed Hassan Ahmed, MD – Mayo Clinic
• 7:00 AM – 9:00 AM

  MP79-18: Impact of Metabolic Diseases and Drugs on Prostate Cancer Patients Receiving Androgen Deprivation Therapy
  Jiun Hung Geng, MD
• 7:00 AM – 9:00 AM

  MP79-19: Population based analysis of rates of use of novel hormonal agents at the end-of-life in men with castration-resistant prostate cancer
  Jason Hu – McGill University
• 7:00 AM – 9:00 AM

  MP79-20: Assessing the optimal timing of postoperative treatments after radical prostatectomy in patients with node-positive prostate cancer: results from a large, multi-institutional series
  Carlo Bravi, MD